Supernus Pharmaceuticals Total Long Term Liabilities 2011-2025 | SUPN

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Supernus Pharmaceuticals total long term liabilities from 2011 to 2025. Total long term liabilities can be defined as the sum of all non-current liabilities.

Supernus Pharmaceuticals Total Long Term Liabilities 2011-2025 | SUPN

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Supernus Pharmaceuticals total long term liabilities from 2011 to 2025. Total long term liabilities can be defined as the sum of all non-current liabilities.

Related Stocks
Company Name	Market Cap
Teva Pharmaceutical Industries (TEVA)	$15.5B
Dr Reddy's Laboratories (RDY)	$11.4B
BridgeBio Pharma (BBIO)	$6.4B
Bausch Health Cos (BHC)	$1.9B
Amphastar Pharmaceuticals (AMPH)	$1.1B
Personalis (PSNL)	$282M
Taysha Gene Therapies (TSHA)	$254M
Assembly Biosciences (ASMB)	$75M
Sol-Gel Technologies (SLGL)	$15M
Evoke Pharma (EVOK)	$3M
Teligent (TLGT)	$0M